Literature DB >> 20952424

Acute haemodynamic effects of increase in paced heart rate in heart failure patients recorded with an implantable haemodynamic monitor.

Marcus Ståhlberg1, Roger Kessels, Cecilia Linde, Frieder Braunschweig.   

Abstract

AIMS: The aim of this study was to investigate the acute effects of different biventricularly paced heart rates (pHRs) on right ventricular (RV) haemodynamics in heart failure (HF) patients with an implantable haemodynamic monitor (IHM). METHODS AND
RESULTS: At rest, seven pHRs, range 60-120 bpm (steps of 10), were randomly programmed and maintained for 60 s in 10 patients (male, 65±12 years, New York Heart Association II-III). Right ventricular systolic (RVSP) and diastolic pressures, estimated pulmonary artery diastolic (ePAD) pressure, and RV+dP/dt were recorded beat-to-beat using the IHM. Cardiac output (CO) was estimated from the RV pressure waveforms and arterial blood pressure was measured (Portapres®). To compare the haemodynamic effects of increased pHR at rest to that of spontaneous, sinus-driven heart rate (HR) increase, patients also performed a symptom-limited bicycle exercise. At rest, RV+dP/dt increased significantly with elevated pHR (P, main effect, <0.001), whereas filling pressures (ePAD and RVSP) decreased significantly in the range 60-100 bpm (P<0.03 and P<0.003, respectively) but tended to increase or level out at pHRs>00 bpm. At a pHR of 100 bpm, ePAD was 1.4 mmHg lower compared with 60 bpm (P<0.01). Cardiac output increased gradually with elevated pHR at rest (P<0.001). Both total peripheral and estimated pulmonary arterial resistance significantly decreased with increased pHR. During exercise-induced maximum HR increase, RV+dP/dt, ePAD, and CO were all significantly higher compared with the corresponding pHR at rest.
CONCLUSION: During cardiac resynchronization therapy in HF patients, the force frequency relationship is present in the RV, as increasing the pHR in the range 60-100 bpm results in decreased filling pressures and increased CO.

Entities:  

Mesh:

Year:  2010        PMID: 20952424     DOI: 10.1093/europace/euq354

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.

Authors:  Steven Hsu; Brian A Houston; Emmanouil Tampakakis; Anita C Bacher; Parker S Rhodes; Stephen C Mathai; Rachel L Damico; Todd M Kolb; Laura K Hummers; Ami A Shah; Zsuzsanna McMahan; Celia P Corona-Villalobos; Stefan L Zimmerman; Fredrick M Wigley; Paul M Hassoun; David A Kass; Ryan J Tedford
Journal:  Circulation       Date:  2016-05-11       Impact factor: 29.690

2.  Clinical validation of a real-time data processing system for cardiac output and arterial pressure measurement during intraoperative biventricular pacing optimization.

Authors:  Christopher K Johnson; Santos E Cabreriza; Rana L Sahar; Alexander Rusanov; Daniel Y Wang; Bin Cheng; Mira S Gendy; T Alexander Quinn; Henry Michael Spotnitz
Journal:  ASAIO J       Date:  2012 May-Jun       Impact factor: 2.872

3.  Outcomes of cardiac resynchronization therapy in patients with atrial fibrillation accompanied by slow ventricular response.

Authors:  Jin Kyung Hwang; Hye Bin Gwag; Kyoung-Min Park; Young Keun On; June Soo Kim; Seung-Jung Park
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.240

4.  Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial.

Authors:  Adam Ali Ghotbi; Mikael Sander; Lars Køber; Berit Th Philbert; Finn Gustafsson; Christoffer Hagemann; Andreas Kjær; Peter K Jacobsen
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

5.  Effect of increasing heart rate on finger photoplethysmography fitness index (PPGF) in subjects with implanted cardiac pacemakers.

Authors:  Amilia Aminuddin; Isabella Tan; Mark Butlin; Alberto P Avolio; Hosen Kiat; Edward Barin; Nor Anita Megat Mohd Nordin; Kalaivani Chellappan
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.